NeuMoDx™ MOLECULAR SYSTEMS
INTEGRATING THE DIAGNOSTIC PROCESS
The NeuMoDx™ Molecular Systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result.”
NeuMoDx™ Molecular Systems provide the industry’s first true continuous random-access solution and is scalable to meet the needs of the modern clinical laboratory. The ability to load samples and testing consumables on the fly offers up to 8 hours of operator walkaway capability. Room temperature stable reagents and consumables dramatically reduce waste resulting in unmatched flexibility. Liquid handling and transport is achieved through proven robotic technologies. Our proprietary and unitized microfluidic cartridge features autonomous lanes allowing for simultaneous processing of sample types and varying assays. This unique integration of robotics with advanced microfluidics, reduces operation to three simple steps providing industry leading usability. These capabilities dramatically improve lab productivity and the ability to provide clinicians with critical information in a timely manner.What we do
Seriously, it is an amazing piece of gear, and I think they found a really good niche because you can load any assay on it and it is going to work.
I thought there were a lot of interesting things in it combining, extraction and going through the whole process and doing the PCR and getting the Ct values out there and curves. I thought it was very smart.
We are looking at more ease of use with support workers and MLAs… where we are looking at a simple solution of loading a sample into a machine have having a result. I think this machine has finally come out with an answer.
Very wonderful and very useful…no hands on time… like an automated machine for serology, and I think it is the future.
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.